Meropenem Dosing for Newborns
For neonates, administer meropenem 20 mg/kg intravenously, with dosing intervals determined by both postnatal age and weight. 1, 2
Dosing Algorithm by Age and Weight
Neonates 0-7 Days Postnatal Age:
- All weights: 20 mg/kg every 12 hours 1
Neonates >7 Days Postnatal Age:
Alternative FDA-Approved Dosing for Infants <3 Months:
For complicated intra-abdominal infections specifically, the FDA label provides gestational age (GA) and postnatal age (PNA)-based dosing 2:
- GA <32 weeks AND PNA <2 weeks: 20 mg/kg every 12 hours
- GA <32 weeks AND PNA ≥2 weeks: 20 mg/kg every 8 hours
- GA ≥32 weeks AND PNA <2 weeks: 20 mg/kg every 8 hours
- GA ≥32 weeks AND PNA ≥2 weeks: 30 mg/kg every 8 hours
Administration Details
Infusion time: Administer as a 30-minute intravenous infusion 2. The FDA label specifies 15-30 minutes for standard dosing, though prolonged 4-hour infusions may improve outcomes in Gram-negative late-onset sepsis 3.
Special considerations for Pseudomonas infections: When treating infections caused by Pseudomonas aeruginosa, consider using 20 mg/kg every 8 hours regardless of weight, or even 40 mg/kg every 8 hours for severe infections 4, 5.
Important Clinical Caveats
Renal function monitoring is critical. Meropenem clearance correlates strongly with estimated creatinine clearance and postconceptional age 6, 7. Neonates with renal impairment require dose adjustment, though specific pediatric renal dosing guidelines are limited 2.
Meningitis requires higher doses. For bacterial meningitis in neonates ≥3 months, increase to 40 mg/kg every 8 hours (maximum 2 grams) 4, 2. However, meropenem is not FDA-approved for meningitis in neonates <3 months of age.
Prolonged infusion may be superior. Recent evidence suggests that 4-hour infusions achieve better pharmacodynamic targets and clinical outcomes compared to 30-minute infusions, particularly for Gram-negative sepsis 3, 8. This approach resulted in higher microbiologic eradication rates (significantly better at day 7), lower mortality, and reduced acute kidney injury in one randomized trial 3.
Target attainment challenges exist. Monte Carlo simulations demonstrate that standard dosing may not consistently achieve optimal pharmacokinetic targets (free drug concentration >MIC for 100% of the dosing interval) against resistant organisms with MIC ≥4 mg/L 6, 7, 9. For such pathogens, consider 40 mg/kg doses with prolonged infusion.
Gestational age matters more than postnatal age. Pharmacokinetic studies show that postconceptional age and serum creatinine are better predictors of meropenem clearance than postnatal age alone 6, 7. Preterm neonates have significantly lower clearance and may achieve higher trough concentrations 9.
The IDSA guideline recommendations 1 align with FDA labeling 2 and are supported by robust pharmacokinetic data in neonatal populations 8, 6, 7. The weight-based and age-based stratification accounts for developmental changes in renal function that significantly impact meropenem elimination in this vulnerable population.